The inflammasome in atherosclerosis and type 2 diabetes

Science Translational Medicine

Volumn 3, Issue 81, 2011, Pages

  Masters, Seth L ^a   Latz, Eicke ^b,c   O'Neill, Luke A J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; AMYLIN; APOLIPOPROTEIN E; CERAMIDE; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; INSULIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA NEUTRALIZING ANTIBODY; LOW DENSITY LIPOPROTEIN; NEUTRALIZING ANTIBODY; NUCLEATING RECEPTOR PROTEIN; PROINSULIN; PROTEIN ASC; REACTIVE OXYGEN METABOLITE; RECEPTOR PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIMVASTATIN; THIOREDOXIN INTERACTING PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; HYPERLIPOPROTEINEMIA TYPE 3; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LYSOSOME; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHAGOCYTOSIS; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; REVIEW; ANIMAL; ARTICLE; IMMUNOLOGY; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA;

EID: 79955693448     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001902     Document Type: Review

References (90)

1. S. L. Masters, A. Dunne, S. L. Subramanian, R. L. Hull, G. M. Tannahill, F. A. Sharp, C. Becker, L. Franchi, E. Yoshihara, Z. Chen, N. Mullooly, L. A. Mielke, J. Harris, R. C. Coll, K. H. Mills, K. H. Mok, P. Newsholme, G. Nu?ez, J. Yodoi, S. E. Kahn, E. C. Lavelle, L. A. O'Neill, Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
2. B. Vandanmagsar, Y. H. Youm, A. Ravussin, J. E. Galgani, K. Stadler, R. L. Mynatt, E. Ravussin, J. M. Stephens, V. D. Dixit, The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
3. R. Zhou, A. Tardivel, B. Thorens, I. Choi, J. Tschopp, Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2010).
4. P. Duewell, H. Kono, K. J. Rayner, C. M. Sirois, G. Vladimer, F. G. Bauernfeind, G. S. Abela, L. Franchi, G. Nuñez, M. Schnurr, T. Espevik, E. Lien, K. A. Fitzgerald, K. L. Rock, K. J. Moore, S. D. Wright, V. Hornung, E. Latz, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
5. C. M. Larsen, M. Faulenbach, A. Vaag, A. Vølund, J. A. Ehses, B. Seifert, T. Mandrup-Poulsen, M. Y. Donath, Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007). (Pubitemid 46588416)
6. S. M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998). (Pubitemid 28350165)
7. J. C. Pickup, M. A. Crook, Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41, 1241-1248 (1998). (Pubitemid 28449093)
8. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, A. W. Ferrante Jr., Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796-1808 (2003). (Pubitemid 38063703)
9. H. Shi, I. Tzameli, C. Bjørbaek, J. S. Flier, Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J. Biol. Chem. 279, 34733-34740 (2004). (Pubitemid 39318104)
10. K. Ueki, T. Kondo, C. R. Kahn, Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24, 5434-5446 (2004). (Pubitemid 38738176)
11. A. Calver, J. Collier, P. Vallance, Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest. 90, 2548-2554 (1992). (Pubitemid 23010077)
12. A. M. Zeiher, H. Drexler, H. Wollschläger, H. Just, Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 83, 391-401 (1991).
13. J. L. Mehta, N. Rasouli, A. K. Sinha, B. Molavi, Oxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunction. Int. J. Biochem. Cell Biol. 38, 794-803 (2006). (Pubitemid 43363412)
14. E. Thorp, G. Li, T. A. Seimon, G. Kuriakose, D. Ron, I. Tabas, Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe-/-and Ldlr-/-mice lacking CHOP. Cell Metab. 9, 474-481 (2009).
15. F. Kim, M. Pham, I. Luttrell, D. D. Bannerman, J. Tupper, J. Thaler, T. R. Hawn, E. W. Raines, M. W. Schwartz, Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100, 1589-1596 (2007). (Pubitemid 46897262)
16. M. Poggi, D. Bastelica, P. Gual, M. A. Iglesias, T. Gremeaux, C. Knauf, F. Peiretti, M. Verdier, I. Juhan-Vague, J. F. Tanti, R. Burcelin, M. C. Alessi, C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 50, 1267-1276 (2007). (Pubitemid 46701560)
17. D. M. Tsukumo, M. A. Carvalho-Filho, J. B. Carvalheira, P. O. Prada, S. M. Hirabara, A. A. Schenka, E. P. Araújo, J. Vassallo, R. Curi, L. A. Velloso, M. J. Saad, Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56, 1986-1998 (2007). (Pubitemid 47195825)
18. K. S. Michelsen, M. H. Wong, P. K. Shah, W. Zhang, J. Yano, T. M. Doherty, S. Akira, T. B. Rajavashisth, M. Arditi, Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice defi cient in apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 101, 10679-10684 (2004). (Pubitemid 38955802)
19. X. Liu, T. Ukai, H. Yumoto, M. Davey, S. Goswami, F. C. Gibson 3rd, C. A. Genco, Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 196, 146-154 (2008).
20. A. E. Mullick, P. S. Tobias, L. K. Curtiss, Modulation of atherosclerosis in mice by Toll-like receptor 2. J. Clin. Invest. 115, 3149-3156 (2005). (Pubitemid 41567579)
21. J. A. Ehses, D. T. Meier, S. Wueest, J. Rytka, S. Boller, P. Y. Wielinga, A. Schraenen, K. Lemaire, S. Debray, L. Van Lommel, J. A. Pospisilik, O. Tschopp, S. M. Schultze, U. Malipiero, H. Esterbauer, H. Ellingsgaard, S. Rütti, F. C. Schuit, T. A. Lutz, M. Böni-Schnetzler, D. Konrad, M. Y. Donath, Toll-like receptor 2-defi cient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 53, 1795-1806 (2010).
22. K. Schroder, J. Tschopp, The inflammasomes. Cell 140, 821-832 (2010).
23. K. Bendtzen, T. Mandrup-Poulsen, J. Nerup, J. H. Nielsen, C. A. Dinarello, M. Svenson, Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232, 1545-1547 (1986). (Pubitemid 16061563)
24. C. A. Dinarello, M. Y. Donath, T. Mandrup-Poulsen, Role of IL-1beta in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17, 314-321 (2010) (Aug).
25. J. Spranger, A. Kroke, M. Möhlig, K. Hoffmann, M. M. Bergmann, M. Ristow, H. Boeing, A. F. Pfeiffer, Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52, 812-817 (2003). (Pubitemid 36323590)
26. A. del Rey, H. Besedovsky, Interleukin 1 affects glucose homeostasis. Am. J. Physiol. 253, R794-R798 (1987).
27. P. R. Ling, B. R. Bistrian, B. Mendez, N. W. Istfan, Effects of systemic infusions of endotoxin, tumor necrosis factor, and interleukin-1 on glucose metabolism in the rat: Relationship to endogenous glucose production and peripheral tissue glucose uptake. Metabolism 43, 279-284 (1994). (Pubitemid 24100495)
28. D. L. Eizirik, E. Strandell, K. Bendtzen, S. Sandler, Functional characteristics of rat pancreatic islets maintained in culture after exposure to human interleukin 1. Diabetes 37, 916-919 (1988). (Pubitemid 19043721)
29. C. Lamacchia, G. Palmer, L. Bischoff, E. Rodriguez, D. Talabot-Ayer, C. Gabay, Distinct roles of hepatocyte-and myeloid cell-derived IL-1 receptor antagonist during endotoxemia and sterile inflammation in mice. J. Immunol. 185, 2516-2524 (2010).
30. P. S. Olofsson, Y. Sheikine, K. Jatta, M. Ghaderi, A. Samnegård, P. Eriksson, A. Sirsjö, A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta: interleukin-1 receptor antagonist balance in atherosclerosis. Circ. J. 73, 1531-1536 (2009).
31. E. Somm, E. Henrichot, A. Pernin, C. E. Juge-Aubry, P. Muzzin, J. M. Dayer, M. J. Nicklin, C. A. Meier, Decreased fat mass in interleukin-1 receptor antagonist-defi cient mice: Impact on adipogenesis, food intake, and energy expenditure. Diabetes 54, 3503-3509 (2005). (Pubitemid 43334342)
32. L. D. Wogensen, J. Reimers, J. Nerup, V. Kolb-Bachofen, K. D. Kröncke, T. Almdal, T. Mandrup-Poulsen, Repetitive in vivo treatment with human recombinant interleukin-1 beta modifi es beta-cell function in normal rats. Diabetologia 35, 331-339 (1992).
33. J. A. Ehses, G. Lacraz, M. H. Giroix, F. Schmidlin, J. Coulaud, N. Kassis, J. C. Irminger, M. Kergoat, B. Portha, F. Homo-Delarche, M. Y. Donath, IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U.S.A. 106, 13998-14003 (2009).
34. N. S. Sauter, F. T. Schulthess, R. Galasso, L. W. Castellani, K. Maedler, The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 149, 2208-2218 (2008). (Pubitemid 351574505)
35. O. Osborn, S. E. Brownell, M. Sanchez-Alavez, D. Salomon, H. Gram, T. Bartfai, Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44, 141-148 (2008).
36. A. M. Owyang, K. Maedler, L. Gross, J. Yin, L. Esposito, L. Shu, J. Jadhav, E. Domsgen, J. Bergemann, S. Lee, S. Kantak, XOMA 052, an anti-IL-1beta monoclonal antibody, improves glucose control and beta-cell function in the diet-induced obesity mouse model. Endocrinology 151, 2515-2527 (2010) (Jun).
37. C. M. Larsen, M. Faulenbach, A. Vaag, J. A. Ehses, M. Y. Donath, T. Mandrup-Poulsen, Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32, 1663-1668 (2009).
38. J. Galea, J. Armstrong, P. Gadsdon, H. Holden, S. E. Francis, C. M. Holt, Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16, 1000-1006 (1996). (Pubitemid 26266899)
39. C. F. Moyer, D. Sajuthi, H. Tulli, J. K. Williams, Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am. J. Pathol. 138, 951-960 (1991).
40. Y. J. Geng, Q. Wu, M. Muszynski, G. K. Hansson, P. Libby, Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-a, and interleukin-1 beta. Arterioscler. Thromb. Vasc. Biol. 16, 19-27 (1996). (Pubitemid 26026927)
41. J. D. Hosenpud, The effects of interleukin 1 on myocardial function and metabolism. Clin. Immunol. Immunopathol. 68, 175-180 (1993). (Pubitemid 23278070)
42. B. J. Rollins, T. Yoshimura, E. J. Leonard, J. S. Pober, Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am. J. Pathol. 136, 1229-1233 (1990). (Pubitemid 20210321)
43. S. Lindemann, N. D. Tolley, D. A. Dixon, T. M. McIntyre, S. M. Prescott, G. A. Zimmerman, A. S. Weyrich, Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J. Cell Biol. 154, 485-490 (2001). (Pubitemid 34286155)
44. H. Kirii, T. Niwa, Y. Yamada, H. Wada, K. Saito, Y. Iwakura, M. Asano, H. Moriwaki, M. Seishima, Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoEdefi cient mice. Arterioscler. Thromb. Vasc. Biol. 23, 656-660 (2003). (Pubitemid 36438080)
45. M. J. Nicklin, D. E. Hughes, J. L. Barton, J. M. Ure, G. W. Duff, Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 191, 303-312 (2000).
46. B. Thorand, H. Kolb, J. Baumert, W. Koenig, L. Chambless, C. Meisinger, T. Illig, S. Martin, C. Herder, Elevated levels of interleukin-18 predict the development of type 2 dia-betes: Results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 54, 2932-2938 (2005). (Pubitemid 41401089)
47. S. Blankenberg, L. Tiret, C. Bickel, D. Peetz, F. Cambien, J. Meyer, H. J. Rupprecht, AtheroGene Investigators, Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106, 24-30 (2002). (Pubitemid 34747437)
48. S. R. Thompson, S. E. Humphries, Interleukin-18 genetics and inflammatory disease susceptibility. Genes Immun. 8, 91-99 (2007). (Pubitemid 46390906)
49. Z. Mallat, A. Corbaz, A. Scoazec, S. Besnard, G. Lesèche, Y. Chvatchko, A. Tedgui, Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104, 1598-1603 (2001). (Pubitemid 32947520)
50. E. C. Lewis, C. A. Dinarello, Responses of IL-18-and IL-18 receptor-defi cient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 16852-16857 (2006). (Pubitemid 44737342)
51. R. de Nooijer, J. H. von der Thüsen, C. J. Verkleij, J. Kuiper, J. W. Jukema, E. E. van der Wall, J. C. van Berkel, E. A. Biessen, Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-defi cient mice. Arterioscler. Thromb. Vasc. Biol. 24, 2313-2319 (2004). (Pubitemid 39658035)
52. H. W. Tan, X. Liu, X. P. Bi, S. S. Xing, L. Li, H. P. Gong, M. Zhong, Z. H. Wang, Y. Zhang, W. Zhang, IL-18 overexpression promotes vascular inflammation and remodeling in a rat model of metabolic syndrome. Atherosclerosis 208, 350-357 (2010).
53. E. Latz, The inflammasomes: Mechanisms of activation and function. Curr. Opin. Immunol. 22, 28-33 (2010).
54. F. Martinon, A. Mayor, J. Tschopp, The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
55. J. P. Ting, B. K. Davis, CATERPILLER: A novel gene family important in immunity, cell death, and diseases. Annu. Rev. Immunol. 23, 387-414 (2005). (Pubitemid 40563175)
56. C. M. Cruz, A. Rinna, H. J. Forman, A. L. Ventura, P. M. Persechini, D. M. Ojcius, ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages. J. Biol. Chem. 282, 2871-2879 (2007). (Pubitemid 47084344)
57. C. Dostert, V. Pétrilli, R. Van Bruggen, C. Steele, B. T. Mossman, J. Tschopp, Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008). (Pubitemid 351928351)
58. A. Sekiyama, H. Ueda, S. Kashiwamura, R. Sekiyama, M. Takeda, K. Rokutan, H. Okamura, A stress-induced, superoxide-mediated caspase-1 activation pathway causes plasma IL-18 upregulation. Immunity 22, 669-677 (2005). (Pubitemid 40814498)
59. V. Hornung, F. Bauernfeind, A. Halle, E. O. Samstad, H. Kono, K. L. Rock, K. A. Fitzgerald, E. Latz, Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
60. T. Bergsbaken, S. L. Fink, B. T. Cookson, Pyroptosis: Host cell death and inflammation. Nat. Rev. Microbiol. 7, 99-109 (2009).
61. V. Pétrilli, S. Papin, C. Dostert, A. Mayor, F. Martinon, J. Tschopp, Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007). (Pubitemid 47278844)
62. T. Fernandes-Alnemri, J. Wu, J. W. Yu, P. Datta, B. Miller, W. Jankowski, S. Rosenberg, J. Zhang, E. S. Alnemri, The pyroptosome: A supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14, 1590-1604 (2007). (Pubitemid 47278845)
63. R. Zhou, A. Tardivel, B. Thorens, I. Choi, J. Tschopp, Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2010).
64. A. Shalev, C. A. Pise-Masison, M. Radonovich, S. C. Hoff-mann, B. Hirshberg, J. N. Brady, D. M. Harlan, Oligonucleotide microarray analysis of intact human pancreatic islets: Identifi cation of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 143, 3695-3698 (2002). (Pubitemid 34925747)
65. K. Maedler, P. Sergeev, F. Ris, J. Oberholzer, H. I. Joller-Jemelka, G. A. Spinas, N. Kaiser, P. A. Halban, M. Y. Donath, Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851-860 (2002).
66. M. Böni-Schnetzler, J. Thorne, G. Parnaud, L. Marselli, J. A. Ehses, J. Kerr-Conte, F. Pattou, P. A. Halban, G. C. Weir, M. Y. Donath, Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93, 4065-4074 (2008).
67. B. B. Lowell, G. I. Shulman, Mitochondrial dysfunction and type 2 diabetes. Science 307, 384-387 (2005). (Pubitemid 40139974)
68. N. Welsh, M. Cnop, I. Kharroubi, M. Bugliani, R. Lupi, P. Marchetti, D. L. Eizirik, Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes 54, 3238-3244 (2005). (Pubitemid 43334380)
69. P. D. Venieratos, G. I. Drossopoulou, K. D. Kapodistria, E. C. Tsilibary, P. V. Kitsiou, High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells. Cell. Signal. 22, 791-800 (2010) (May).
70. M. Lamkanfi , J. L. Mueller, A. C. Vitari, S. Misaghi, A. Fedorova, K. Deshayes, W. P. Lee, H. M. Hoffman, V. M. Dixit, Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187, 61-70 (2009).
71. G. J. Cooper, A. C. Willis, A. Clark, R. C. Turner, R. B. Sim, K. B. Reid, Purifi cation and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. U.S.A. 84, 8628-8632 (1987). (Pubitemid 18033465)
72. P. Westermark, C. Wernstedt, E. Wilander, D. W. Hayden, T. D. O'Brien, K. H. Johnson, Amyloid fi brils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. U.S.A. 84, 3881-3885 (1987). (Pubitemid 17088383)
73. C. F. Howard Jr., Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29, 301-306 (1986). (Pubitemid 16080927)
74. S. Zraika, R. L. Hull, C. B. Verchere, A. Clark, K. J. Potter, P. E. Fraser, D. P. Raleigh, S. E. Kahn, Toxic oligomers and islet beta cell death: Guilty by association or convicted by circumstantial evidence? Diabetologia 53, 1046-1056 (2010) (Jun).
75. M. Arnush, M. R. Heitmeier, A. L. Scarim, M. H. Marino, P. T. Manning, J. A. Corbett, IL-1 produced and released endogenously within human islets inhibits beta cell function. J. Clin. Invest. 102, 516-526 (1998). (Pubitemid 28376154)
76. J. A. Ehses, A. Perren, E. Eppler, P. Ribaux, J. A. Pospisilik, R. Maor-Cahn, X. Gueripel, H. Ellingsgaard, M. K. Schneider, G. Biollaz, A. Fontana, M. Reinecke, F. Homo-Delarche, M. Y. Donath, Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56, 2356-2370 (2007). (Pubitemid 47358243)
77. S. J. Richardson, A. Willcox, A. J. Bone, A. K. Foulis, N. G. Morgan, Islet-associated macrophages in type 2 diabetes. Diabetologia 52, 1686-1688 (2009).
78. R. Stienstra, L. A. Joosten, T. Koenen, B. van Tits, J. A. van Diepen, S. A. van den Berg, P. C. Rensen, P. J. Voshol, G. Fantuzzi, A. Hijmans, S. Kersten, M. Müller, W. B. van den Berg, N. van Rooijen, M. Wabitsch, B. J. Kullberg, J. W. van der Meer, T. Kanneganti, C. J. Tack, M. G. Netea, The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593-605 (2010).
79. K. Rajamäki, J. Lappalainen, K. Oörni, E. Välimäki, S. Matikainen, P. T. Kovanen, K. K. Eklund, Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS ONE 5, e11765 (2010).
80. H. Bessler, H. Salman, M. Bergman, R. Straussberg, M. Djaldetti, In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin. Immunol. 117, 73-77 (2005). (Pubitemid 41725472)
81. J. P. Drenth, L. Cuisset, G. Grateau, C. Vasseur, S. D. van de Velde-Visser, J. G. N. de Jong, J. S. Beckmann, J. W. van der Meer, M. Delpech, International Hyper-IgD Study Group, Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat. Genet. 22, 178-181 (1999). (Pubitemid 29264814)
82. E. J. Bodar, J. C. van der Hilst, J. P. Drenth, J. W. van der Meer, A. Simon, Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: Introducing a vaccination provocation model. Neth. J. Med. 63, 260-264 (2005). (Pubitemid 41179436)
83. C. R. Stewart, L. M. Stuart, K. Wilkinson, J. M. van Gils, J. Deng, A. Halle, K. J. Rayner, L. Boyer, R. Zhong, W. A. Frazier, A. Lacy-Hulbert, J. El Khoury, D. T. Golenbock, K. J. Moore, CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11, 155-161 (2010).
84. Y. I. Miller, S. Viriyakosol, C. J. Binder, J. R. Feramisco, T. N. Kirkland, J. L. Witztum, Minimally modifi ed LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278, 1561-1568 (2003). (Pubitemid 36801384)
85. E. Apolinario, S. Ferderbar, E. C. Pereira, M. C. Bertolami, A. Faludi, O. Monte, A. R. Gagliardi, H. T. Xavier, D. S. P. Abdalla, Minimally modifi ed (electronegative) LDL-and Anti-LDL-autoantibodies in diabetes mellitus and impaired glucose tolerance. Int J Atheroscler 1, 42-47 (2006).
86. L. A. Joosten, M. G. Netea, E. Mylona, M. I. Koenders, R. K. S. Malireddi, M. Oosting, R. Stienstra, F. L. van de Veerdonk, A. F. Stalenhoef, E. J. Giamarellos-Bourboulis, T.-D. Kanneganti, J. W. M. van der Meer, Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248 (2010).
87. M. Böni-Schnetzler, S. Boller, S. Debray, K. Bouzakri, D. T. Meier, R. Prazak, J. Kerr-Conte, F. Pattou, J. A. Ehses, F. C. Schuit, M. Y. Donath, Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150, 5218-5229 (2009).
88. D. Westermann, S. Van Linthout, S. Dhayat, N. Dhayat, F. Escher, C. Bücker-Gärtner, F. Spillmann, M. Noutsias, A. Riad, H. P. Schultheiss, C. Tschöpe, Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56, 1834-1841 (2007). (Pubitemid 47025453)
89. S. R. Daniels, F. R. Greer, Committee on Nutrition, Lipid screening and cardiovascular health in childhood. Pediatrics 122, 198-208 (2008).
90. Competing interests: The authors declare no competing interests.